← Return to Good PSA/MRI active surveillance results still require fusion biopsy?

Discussion

Good PSA/MRI active surveillance results still require fusion biopsy?

Prostate Cancer | Last Active: Oct 25 2:40pm | Replies (30)
Comment receiving replies
@bens1

@jeffmarc
I just contacted them and got a quick answer regarding the MPS2 test. They said:

"MPS 2.0 does not identify the biological recurrence of prostate cancer.

MPS 2.0 is a non-invasive urine test that analyzes 18 unique biomarkers and accurately quantifies the personalized risk of clinically significant prostate cancer (csPCa) for men with elevated PSA or abnormal DRE findings. The test results offer you and your Urologist the clear, accurate insights you need to decide the next clinical steps.

Researchers are studying the utility of MPS 2.0 in patients on active surveillance and in patients newly diagnosed with prostate cancer considering active surveillance.

However, MPS 2.0 was developed and validated in patients not previously diagnosed with prostate cancer. Therefore, it has not been evaluated in patients on active surveillance and should not be used in these cases."

Jump to this post

Replies to "@jeffmarc I just contacted them and got a quick answer regarding the MPS2 test. They said:..."
oct172024 | @oct172024 | Oct 18 11:45am

Recommendation not to use MPS 2.0 for those on AS seems conservative. Understand that testing for those on AS is not completed, but seems logical to expect similar good results that could help those on AS avoid additional biopsies.
Encouraged by what appears to be a growing list of good alternatives to avoid biopsies- (personal goal of mine!)

VIEW AND REPLY